In response: Considerations regarding compounding pharmacies and GLP-1 agonists

Am J Emerg Med. 2024 Jun:80:197-198. doi: 10.1016/j.ajem.2024.03.037. Epub 2024 Apr 6.

Authors

Brit Long¹, Jessica Pelletier², Alex Koyfman³, Rachel E Bridwell⁴

Affiliations

¹ Department of Emergency, Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA. Electronic address: Brit.long@yahoo.com.
² Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, USA.
³ Department of Emergency Medicine, UT, Southwestern, Dallas, TX, USA.
⁴ Department of Emergency Medicine, Madigan Army Medical Center, Tacoma, WA, USA.

PMID: 38600000
DOI: 10.1016/j.ajem.2024.03.037

No abstract available

Keywords: Adverse event; Complication; Compounding; Diabetes; Endocrine; GLP-1 agonist; Liraglutide; Semaglutide; Side effect; Weight loss.

Publication types

Letter

MeSH terms

Drug Compounding* / standards
Glucagon-Like Peptide 1 / agonists
Humans
Hypoglycemic Agents / therapeutic use
Pharmacies / standards

Substances

Glucagon-Like Peptide 1
Hypoglycemic Agents